circulating cell-free DNA

This Week in PLOS

In PLOS this week: metabolite profiles of typhoid fever, shifts in cell-free DNA levels following exercise, and more.

The firm plans to launch a nasopharyngeal carcinoma test in Asia this year and is developing breast cancer tests to supplement mammograms.

Milwaukee, Wis.-based TAI Diagnostics is developing a PCR-based assay for cell-free DNA as a way to monitor the health of transplanted organs.

Technologies gained one of their first solid footholds in the clinical care of cancer patients with adoption into the treatment paradigm of lung cancer, while researchers turned their eyes to proving utility in other niches.

The China Food and Drug Administration had also previously accredited both the NIFTY test and the BGISEQ sequencing platform.

The new European initiative promises to deliver multiple new tests and methods for improving the treatment of breast cancer and rectal cancer.

The company said that it is working on cfDNA claim extensions for various PCR and NGS assays in its portfolio, which would be compatible with the new extraction system.

Labs reported on their work with kits from both Roche and Thermo Fisher, both of which have launched new commercial liquid biopsy products in recent years.

The company presented new data from its validation of the PCR-based approach at a conference, citing plans to advance the kit for monitoring and early detection applications.

Participants shared data from head-to-head assay comparisons, reflected on the advancement of NGS and digital PCR methods, and discussed new standardization projects.

Pages

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.